Advanced Optics Electronics Inc. Confirms News of Biomoda's Biotech Consultant; Biomoda Moving Through NASD Exam Process.Business Editors ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Sept. 18, 2003 Herbert L. Whitaker Jr., Ph.D. in chemical engineering and Johnson & Johnson's former director of technology transfer before becoming president/CEO of Lovelace Scientific Resources, will serve as biotech consultant with Biomoda Inc. Dr. Whitaker has an extensive background in clinical research project management and clinical trials and has recently focused his efforts on molecular toxicology toxicology, study of poisons, or toxins, from the standpoint of detection, isolation, identification, and determination of their effects on the human body. Toxicology may be considered the branch of pharmacology devoted to the study of the poisonous effects of drugs. evaluated through micro arrays. Whitaker will initially focus on further developing the product and assisting the movement of its technology to a level where it could be commercialized on a trial basis. Whitaker will also advise on testing array development and protocol design. ADOT's joint development of the Color-Chek device is nearing completion of its developmental stage and is anticipated to be at the final test phase in less than three weeks. The company projects the market for this development to appear quite substantial if pricing is maintained at a reasonable level. Biomoda Inc. (of which ADOT ADOT Arizona Department Of Transportation ADOT Alaska Department of Transportation ADOT Fédération des Associations pour le Don d'Organes et de Tissus Humains ADOT Active Duty Other Than Training ADOT Automatic Digital Optical Tracker ADOT Advanced Display Optimization Tools now directly and indirectly owns and controls 30%) is currently in the NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). examination process and is responding to informational and data requests from staff. Biomoda Inc. anticipates this process will be completed in the very immediate future. Advanced Optics Electronics Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: ADOT) is a technology company based in Albuquerque, N.M. The company maintains an R&D facility and manufacturing plant, and is engaged in building large-scale flat panel displays A thin display screen for computer and TV usage. The first flat panels appeared on laptop computers in the mid-1980s, and the LCD technology became the standard. Stand-alone LCD screens became available for desktop computers in the mid-1990s and exceeded sales of CRTs for the first time utilizing its patented and patent pending technology. In addition to the core business of ADOT, the company has made a strategic technology-oriented investment in Biomoda Inc. Biomoda Inc. is a company that holds patents and patents pending domestically and internationally for the early detection of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . ADOT currently holds directly and indirectly 30% of Biomoda Inc. This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words "believes," "anticipates," "expects," "estimates" and words of similar import. The company's actual results could differ materially from any forward-looking statements, which reflect management's opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. . |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion